GAM Holding’s Juno Therapeutics, Inc. JUNO Stock Holding History

GAM Holding’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50,000	Closed	-$943K	–	1112
2016 Q4	$943K	Buy	+50,000	New	+$1.22M	0.02%	630

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GAM Holding's JUNO Position: Q1 2017 in Review

GAM Holding sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 50,000 shares — an estimated $943K sold.

GAM Holding first reported a position in JUNO in Q4 2016 and held it in 1 quarter. The position peaked at $943K in Q4 2016. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

GAM Holding reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
GAM Holding sold 50,000 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $943K.
GAM Holding first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
GAM Holding's Juno Therapeutics, Inc. position peaked at $943K in Q4 2016.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on GAM Holding's 13F filing for Q1 2017, filed 12 May 2017.